Osteoporotic Fractures among Selective Estrogen Receptor Modulator Users in South Korea: Analysis Using National Claims Database

키워드

참고문헌 (45)

1. van Staa TP, "Epidemiology of fractures in England and Wales", Bone, 29, pp.517~522 (2001)[DOI]
2. Hernlund E, "Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)", Arch Osteoporos, 8, pp.136~ (2013)[DOI]
3. Barrett-Connor E, "Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women", N Engl J Med, 355, pp.125~137 (2006)[DOI]
4. Cauley JA, "Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation", Breast Cancer Res Treat, 65, pp.125~134 (2001)[DOI]
5. Cummings SR, "Lasofoxifene in postmenopausal women with osteoporosis", N Engl J Med, 362, pp.686~696 (2010)[DOI]
6. Silverman SL, "Use of FRAX®-based fracture risk assessments to identify patients who will benefit from osteoporosis therapy", Maturitas, 79, pp.241~247 (2014)[DOI]
7. McCombs JS, "Compliance with drug therapies for the treatment and prevention of osteoporosis", Maturitas, 48, pp.271~287 (2004)[DOI]
8. Fardellone P, "Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women : A systematic review", Clin Ther, 41, pp.1576~1588 (2019)[DOI]
9. Fobelo Lozano MJ, "Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates", Eur J Hosp Pharm, 26, pp.4~9 (2019)[DOI]
10. Ko KR, "Long-term oral bisphosphonate compliance focusing on switching of prescription pattern", Patient Prefer Adherence, 14, pp.2009~2016 (2020)[DOI]
11. 박찬호, "Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration", 대한골대사학회지, 26(1), pp.39~44 (2019), 대한골대사학회
12. Imaz I, "Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk : systematic review and meta-analysis", Osteoporos Int, 21, pp.1943~1951 (2010)[DOI]
13. Akarırmak Ü, "Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis", Acta Orthop Traumatol Turc, 50, pp.415~423 (2016)[DOI]
14. Kuzmanova SI, "Adherence to bisphosphonate therapy in postmenopausal osteoporotic women", Folia Med(Plovdiv), 53, pp.25~31 (2011)[DOI]
15. Ringe JD, "Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women", Curr Med Res Opin, 23, pp.2677~2687 (2007)[DOI]
16. Kothawala P, "Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis", Mayo Clin Proc, 82, pp.1493~1501 (2007)[DOI]
17. Seeyoun Lee, "Risk of Osteoporotic Fracture in Patients with Breast Cancer: Meta-Analysis", 대한골대사학회지, 27(1), pp.27~34 (2020), 대한골대사학회
18. Shaker JL, "Paget’s disease of bone: A review of epidemiology, pathophysiology and management", Ther Adv Musculoskelet Dis, 1, pp.107~125 (2009)[DOI]
19. Johansson H, "Imminent risk of fracture after fracture", Osteoporos Int, 28, pp.775~780 (2017)[DOI]
20. Mok CC, "Raloxifene for prevention of glucocorticoid-induced bone loss : a 12-month randomised double-blinded placebo-controlled trial", Ann Rheum Dis, 70, pp.778~784 (2011)[DOI]
21. Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)[DOI]
22. Curtis JR, "Identification and validation of vertebral compression fractures using administrative claims data", Med Care, 47, pp.69~72 (2009)[DOI]
23. Choi S, "Effect of ethanol in carbon monoxide poisoning and delayed neurologic sequelae : A prospective observational study", PLoS One, 16 (2021)[DOI]
24. 정형석, "Incidence of Osteoporotic Refractures Following Proximal Humerus Fractures in Adults Aged 50 Years and Older in Korea", 대한골대사학회지, 26(2), pp.105~111 (2019), 대한골대사학회
25. Cramer JA, "Medication compliance and persistence : terminology and definitions", Value Health, 11, pp.44~47 (2008)[DOI]
26. Durden E, "Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States", Arch Osteoporos, 12, pp.22~ (2017)[DOI]
27. Faulkner DL, "Patient noncompliance with hormone replacement therapy : a nationwide estimate using a large prescription claims database", Menopause, 5, pp.226~229 (1998)
28. Yood RA, "Compliance with pharmacologic therapy for osteoporosis", Osteoporos Int, 14, pp.965~968 (2003)[DOI]
29. Kripalani S, "Interventions to enhance medication adherence in chronic medical conditions : a systematic review", Arch Intern Med, 167, pp.540~550 (2007)[DOI]
30. Bosmans JE, "Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants", Pharmacoeconomics, 25, pp.25~37 (2007)[DOI]
31. Brunenberg DE, "Cost effectiveness of an adherence-improving programme in hypertensive patients", Pharmacoeconomics, 25, pp.239~251 (2007)[DOI]
32. Huybrechts KF, "Assessment of compliance with osteoporosis treatment and its consequences in a managed care population", Bone, 38, pp.922~928 (2006)[DOI]
33. Caro JJ, "The impact of compliance with osteoporosis therapy on fracture rates in actual practice", Osteoporos Int, 15, pp.1003~1008 (2004)[DOI]
34. Lyu H, "Delayed denosumab injections and fracture risk among patients with osteoporosis : A population-based cohort study", Ann Intern Med, 173, pp.516~526 (2020)[DOI]
35. Tripto-Shkolnik L, "Fracture incidence after denosumab discontinuation : Real-world data from a large healthcare provider", Bone, 130, pp.115150~ (2020)[DOI]
36. Cummings SR, "Vertebral fractures after discontinuation of denosumab : A post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension", J Bone Miner Res, 33, pp.190~198 (2018)[DOI]
37. 안기찬, "Selective Estrogen Receptor Modulators", Asian Spine Journal, 10(4), pp.787~791 (2016), 대한척추외과학회
38. Neele SJ, "Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women", Bone, 30, pp.599~603 (2002)[DOI]
39. Idolazzi L, "Duration of treatment for osteoporosis", Reumatismo, 65, pp.22~35 (2013)[DOI]
40. Barron RL, "Determinants of imminent fracture risk in postmenopausal women with osteoporosis", Osteoporos Int, 31, pp.2103~2111 (2020)[DOI]
41. Bonafede M, "Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data", Arch Osteoporos, 11, pp.26~ (2016)[DOI]
42. Pinedo-Villanueva R, "Imminent fracture risk assessments in the UK FLS setting : implications and challenges", Arch Osteoporos, 14, pp.12~ (2019)[DOI]
43. 윤병호, "Knowledge on Osteoporosis of Prescriber According to Level of Medical Institute", Yonsei Medical Journal, 55(4), pp.1058~1062 (2014), 연세대학교의과대학[DOI]
44. Steiner JF, "The assessment of refill compliance using pharmacy records: methods, validity, and applications", J Clin Epidemiol, 50, pp.105~116 (1997)[DOI]
45. Osterberg L, "Adherence to medication", N Engl J Med, 353, pp.487~497 (2005)[DOI]

관련 논문AI추천